Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $8.60 Consensus Target Price from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received an average rating of “Hold” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.60.

ASMB has been the subject of several analyst reports. William Blair downgraded shares of Assembly Biosciences from an “outperform” rating to a “market perform” rating and set a $3.10 price target for the company. in a report on Thursday, September 2nd. HC Wainwright started coverage on shares of Assembly Biosciences in a research note on Monday, September 13th. They set a “neutral” rating and a $3.50 price objective on the stock. Finally, Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, September 29th.

Shares of ASMB traded down $0.01 during midday trading on Monday, hitting $3.31. 2,164 shares of the stock traded hands, compared to its average volume of 1,085,192. Assembly Biosciences has a 1-year low of $3.09 and a 1-year high of $16.62. The firm has a market capitalization of $148.86 million, a PE ratio of -1.36 and a beta of 0.34. The business’s 50 day moving average price is $3.44 and its two-hundred day moving average price is $3.79.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.11. Assembly Biosciences had a negative net margin of 78.57% and a negative return on equity of 37.80%. As a group, equities analysts forecast that Assembly Biosciences will post -2.31 earnings per share for the current fiscal year.

In other Assembly Biosciences news, CEO John G. Mchutchison sold 12,156 shares of the business’s stock in a transaction dated Monday, August 9th. The shares were sold at an average price of $3.60, for a total value of $43,761.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.90% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Assembly Biosciences by 18.3% in the first quarter. BlackRock Inc. now owns 3,291,676 shares of the biopharmaceutical company’s stock worth $15,142,000 after acquiring an additional 508,368 shares in the last quarter. Platinum Investment Management Ltd. raised its position in Assembly Biosciences by 74.1% in the first quarter. Platinum Investment Management Ltd. now owns 1,431,120 shares of the biopharmaceutical company’s stock worth $6,583,000 after acquiring an additional 609,234 shares in the last quarter. Acadian Asset Management LLC raised its position in Assembly Biosciences by 55.6% in the first quarter. Acadian Asset Management LLC now owns 1,068,526 shares of the biopharmaceutical company’s stock worth $4,917,000 after acquiring an additional 381,709 shares in the last quarter. Geode Capital Management LLC raised its holdings in Assembly Biosciences by 45.7% during the 1st quarter. Geode Capital Management LLC now owns 657,096 shares of the biopharmaceutical company’s stock worth $3,022,000 after buying an additional 206,247 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Assembly Biosciences by 44.3% during the 1st quarter. Renaissance Technologies LLC now owns 577,335 shares of the biopharmaceutical company’s stock worth $2,656,000 after buying an additional 177,335 shares during the period. Hedge funds and other institutional investors own 65.08% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate.

Read More: What are the advantages to having securities held in street name?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.